natgillin/translations-raw huggingface dataset:
Roflumilast is not recommended in women of childbearing potential not using contraception.
Pri bolnicah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije, uporaba roflumilasta ni priporočljiva.
Over the entire study period of 12 weeks, the percentage of patients discontinuing treatment due to any reason was statistically significantly lower in patients initially receiving roflumilast 250 micrograms once a day for 4 weeks followed by roflumilast 500 micrograms once a day for 8 weeks (18.4%) compared to those receiving roflumilast 500 micrograms once a day for 12 weeks (24.6%; Odds Ratio 0.66, 95% CI [0.47, 0.93], p=0.017).
V celotnem 12-tedenskem obdobju študije je bil odstotek bolnikov, ki so prekinili zdravljenje iz katerega koli razloga, statistično značilno nižji pri bolnikih, ki so najprej prejemali roflumilast v odmerku 250 mikrogramov enkrat na dan 4 tedne in nato roflumilast v odmerku 500 mikrogramov enkrat na dan 8 tednov (18,4 %), kot pri tistih, ki so prejemali roflumilast v odmerku 500 mikrogramov enkrat na dan 12 tednov (24,6 %; razmerje obetov 0,66; 95 % interval zaupanja [0,47; 0,93], p = 0,017).
Daxas contains lactose
Zdravilo Daxas vsebuje laktozo
Yellow, D-shaped film-coated tablet of 9 mm, embossed with “D” on one side.
Rumena filmsko obložena tableta v obliki črke D, velika 9 mm, ki ima na eni strani izbočeno črko “D”.
Daxas 500 micrograms film-coated tablets are yellow, D-shaped film-coated tablets, embossed with 'D' on one side.
Daxas 500 mikrogramov filmsko obložene tablete so rumene barve, v obliki črke D in imajo na eni strani izbočeno črko “D”.
Thus, the N-oxide metabolite is considered to be the main contributor to the total PDE4 inhibitory activity in vivo.
Presnovek N-oksid torej prispeva glavnino skupnega inhibitornega delovanja na PDE4 in vivo.
A similar reduction was achieved in the subgroup of patients concomitantly treated with LAMA (rate ratio: 0.77; 95% CI: 0.60 to 0.99) and in the subgroup not treated with LAMA (rate ratio: 0.71; 95% CI: 0.42 to 1.20).
Podobno zmanjšanje je bilo doseženo tako v podskupini bolnikov, ki so se sočasno zdravili z LAMA (razmerje deležev: 0,77; 95 % interval zaupanja: 0,60 do 0,99), kot v podskupini bolnikov, ki se niso zdravili z LAMA (razmerje deležev: 0,71; 95 % interval zaupanja: 0,42 do 1,20).
The percentage of patients experiencing a Treatment Emergent Adverse Event (TEAE) of interest, defined as diarrhoea, nausea, headache, decreased appetite, insomnia, and abdominal pain (secondary endpoint), was nominally statistically significantly lower in patients initially receiving roflumilast 250 micrograms once a day for 4 weeks followed by roflumilast 500 micrograms once a day for 8 weeks (45.4%) compared to those receiving roflumilast 500 micrograms once a day for 12 weeks (54.2%, Odds Ratio 0.63, 95% CI [0.47, 0.83], p=0.001).
Delež bolnikov, pri katerih se je zaradi zdravljenja pojavil kateri od neželenih dogodkov (TEAE - Treatment Emergent Adverse Event) posebnega interesa, ki so bili opredeljeni kot driska, navzea, glavobol, zmanjšanje apetita, nespečnost in bolečine v trebuhu (sekundarni opazovani dogodek), je bil statistično značilno nižji pri bolnikih, ki so najprej prejemali 250 mikrogramov roflumilasta enkrat na dan 4 tedne in nato 500 mikrogramov roflumilasta enkrat na dan 8 tednov (45,4 %), kot pri tistih, ki so prejemali 500 mikrogramov roflumilasta enkrat na dan 12 tednov (54,2 %, razmerje obetov 0,63; 95 % interval zaupanja [0,47; 0,83], p = 0,001).
The rate of experiencing a TEAE of interest for those receiving 500 micrograms every other day for 4 weeks followed by 500 micrograms once a day for 8 weeks was not statistically significantly different to those receiving 500 micrograms once a day for 12 weeks.
Odstotek bolnikov, pri katerih je prišlo do katerega od dogodkov TEAE posebnega interesa, se pri tistih, ki so prejemali 500 mikrogramov vsak drugi dan 4 tedne in nato 500 mikrogramov enkrat na dan 8 tednov, ni statistično značilno razlikoval od tovrstnega odstotka pri tistih, ki so prejemali 500 mikrogramov enkrat na dan 12 tednov.
Due to lack of relevant experience, treatment with roflumilast should not be initiated or existing treatment with roflumilast should be stopped in patients with severe immunological diseases (e.g. HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy), severe acute infectious diseases, cancers (except basal cell carcinoma), or patients being treated with immunosuppressive medicinal products (i.e. methotrexate, azathioprine, infliximab, etanercept, or oral corticosteroids to be taken long-term; except short-term systemic corticosteroids).
Zaradi pomanjkanja ustreznih izkušenj se zdravljenja z roflumilastom ne sme začeti oz. je potekajoče zdravljenje z roflumilastom treba prekiniti pri bolnikih z resnimi boleznimi imunskega sistema (npr. okužbo s HIV, multiplo sklerozo, eritematoznim lupusom, progresivno multifokalno levkoencefalopatijo), resnimi akutnimi infekcijskimi boleznimi, rakom (razen bazalnoceličnega karcinoma) ali bolnikih na imunosupresivnih zdravilih (t.j.
Common side effects (may affect up to 1 in 10 people) - diarrhoea, nausea, stomach ache - weight decrease, decreased appetite - headache
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov): - driska, siljenje na bruhanje, bolečina v trebuhu - zmanjšanje telesne mase, zmanjšan apetit - glavobol.
Reductions were achieved in the subgroup of patients concomitantly treated with LAMA (rate ratio: 0.88; 95% CI: 0.75 to 1.04) and in the subgroup not treated with LAMA (rate ratio: 0.83; 95% CI: 0.62 to 1.12).
Zmanjšanje je bilo doseženo tako v podskupini bolnikov, ki so se sočasno zdravili z LAMA (razmerje deležev: 0,88; 95 % interval zaupanja: 0,75 do 1,04), kot v podskupini bolnikov, ki se niso zdravili z LAMA (razmerje deležev: 0,83; 95 % interval zaupanja: 0,62 do 1,12).
The tested dose of fluvoxamine was 50 mg. A combination of roflumilast with these active substances might lead to an increase of exposure and persistent intolerability.
Pri sočasnem zdravljenju z roflumilastom in s temi učinkovinami se izpostavljenost zdravilu lahko poveča in povzroči trajno intoleranco.
Clinical interaction studies with CYP3A4 inhibitors erythromycin and ketoconazole showed increases of 9% of the total PDE4 inhibitory activity.
V kliničnih študijah medsebojnega delovanja z zaviralcema CYP3A4 eritromicinom in ketokonazolom se je skupno inhibitorno delovanje na PDE4 povečalo za 9 %.
No dose adjustment is necessary.
Prilagajanje odmerka ni potrebno.
Each film-coated tablet (tablet) contains 500 micrograms roflumilast.
Ena filmsko obložena tableta (tableta) vsebuje 500 mikrogramov roflumilasta.
- a medicine containing fluvoxamine (a medicine to treat anxiety disorders and depression), enoxacin (a medicine to treat bacterial infections) or cimetidine (a medicine to treat stomach ulcers or heartburn).
(zdravilo za zdravljenje bakterijskih okužb) ali cimetidin (zdravilo za zdravljenje želodčnih razjed ali zgage).
It is important to continue taking Daxas for as long as prescribed by your doctor, even when you have no symptoms, in order to maintain control of your lung function.
Zaradi vzdrževanja normalnega delovanja pljuč je pomembno, da nadaljujete z jemanjem zdravila Daxas tako dolgo, kot vam je predpisal zdravnik, tudi če nimate simptomov.
The per-protocol Poisson regression analysis and the non-significant sensitivity to drop-out Poisson regression intention-to-treat analysis rate ratios were 0.81 (95% CI: 0.69 to 0.94) and 0.89 (95% CI: 0.77 to 1.02), respectively.
Pri s protokolom določeni analizi Poissonove regresije je razmerje deležev znašalo 0,81 (95 % interval zaupanja: 0,69 do 0,94), pri analizi Poissonove regresije vseh vključenih bolnikov brez občutljivosti na osip pa 0,89 (95 % interval zaupanja: 0,77 do 1,02).
A higher incidence of sleep disorders (mainly insomnia) in patients ≥75 years or older was observed in Study RO-2455-404-RD for patients treated with roflumilast when compared to those treated with placebo (3.9% vs 2.3%).
V študiji RO-2455-404-RD so pri bolnikih, starih 75 let ali starejših, ki so se zdravili z roflumilastom, opazili večjo pojavnost motenj spanja (predvsem nespečnosti) v primerjavi z bolniki, ki so prejemali placebo (3,9 % v primerjavi z 2,3 %).
Since both roflumilast and roflumilast N-oxide contribute to PDE4 inhibitory activity in vivo, pharmacokinetic considerations are based on total PDE4 inhibitory activity (i.e. total exposure to roflumilast and roflumilast N-oxide).
Ker tako roflumilast kot tudi roflumilast N-oksid prispevata k inhibitornemu delovanju na PDE4 in vivo, so farmakokinetične lastnosti opisane za skupno inhibitorno delovanje na PDE4 (t.j.
Total PDE4 inhibitory activity decreased by 9% in patients with severe renal impairment (creatinine clearance 10-30 ml/min).
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina 10-30 ml/min) je bilo skupno inhibitorno delovanje na PDE4 zmanjšano za 9 %.
White to off-white, round tablet, 5 mm in diameter, embossed with “D” on one side and “250” on the other side.
Bela do sivo-bela okrogla tableta premera 5 mm, ki ima na eni strani izbočeno črko “D”, na drugi strani pa oznako “250”.
Each Daxas 250 micrograms tablet contains 250 micrograms roflumilast.
Ena 250 mikrogramska tableta zdravila Daxas vsebuje 250 mikrogramov roflumilasta.
Poisson regression
Poissonova regresija Zmerno Poissonova regresija
Thus, roflumilast treatment is not recommended in patients receiving strong cytochrome P450 enzyme inducers.
Pri bolnikih, ki se zdravijo z močnimi induktorji encima citokroma P450, uporaba roflumilasta tako ni priporočljiva.
The incidence was 2.5% vs 2.2% in patients with a baseline body weight ≥60 kg, treated with roflumilast when compared to those treated with placebo.
Pri bolnikih z izhodiščno telesno maso ≥ 60 kg je pojavnost pri zdravljenju z roflumilastom znašala 2,5 %, pri uporabi placeba pa 2,2 %.
Gamma-GT increased Aspartate aminotransferase (AST) increased
Bolezni jeter, žolčnika in žolčevodov povišana vrednost gama-GT povišana vrednost aspartataminotransferaze (AST)
Nervous system disorders Headache
Bolezni živčevja glavobol tremor vrtoglavica omotica paragevzija
No dose adjustment is necessary in patients receiving these active substances.
Pri bolnikih, ki se zdravijo s temi zdravili, odmerka ni treba prilagajati.
- The other ingredients are: - Core: lactose monohydrate (see section 2 under “Daxas contains lactose”), maize starch, povidone, magnesium stearate, - Coating: hypromellose, Macrogol 4000, titanium dioxide (E171), and iron oxide yellow (E172).
- Obloga: hipromeloza, makrogol 4000, titanov dioksid (E171) in rumeni železov oksid (E172).
Rodent-specific toxicity in the nasal mucosa was observed in repeat-dose toxicity and carcinogenicity studies.
V študijah o toksičnosti ponovljenih odmerkov in karcinogenosti so ugotovili toksično delovanje na nosno sluznico glodavcev.
System Organ Class
Organski sistemi
These findings consisted mainly of gastrointestinal findings (i.e. vomiting, increased gastric secretion, gastric erosions, intestine inflammation) and cardiac findings (i.e. focal haemorrhages, haemosiderin deposits and lympho-histiocytic cell infiltration in the right atria in dogs, and decreased blood pressure and increased heart rate in rats, guinea pigs and dogs).
fokalne krvavitve, depoziti hemosiderina in infiltracija limfo-histiocitnih celic v desnem atriju psov, znižan krvni tlak in povišana frekvenca srca pri podganah, morskih prašičkih in psih).
Respiratory tract infections (excluding Pneumonia)
Bolezni dihal, prsnega koša in mediastinalnega prostora okužbe dihal (brez pljučnice)
A higher incidence of sleep disorders (mainly insomnia) in patients with a baseline body weight <60 kg was observed in Study RO-2455-404-RD for patients treated with roflumilast when compared to those treated with placebo (6.0% vs 1.7%).
V študiji RO-2455-404-RD so pri bolnikih z izhodiščno telesno maso, manjšo od 60 kg, ki so se zdravili z roflumilastom, opazili večjo pojavnost motenj spanja (predvsem nespečnosti) v primerjavi z bolniki, ki so prejemali placebo (6,0 % v primerjavi z 1,7 %).
How to store Daxas
Shranjevanje zdravila Daxas
COPD is a chronic disease of the lungs that results in tightening of the airways (obstruction) and swelling and irritation of the walls of the small air passages (inflammation).
KOPB je kronična pljučna bolezen, ki povzroči zoženje dihalnih poti (obstrukcijo) ter otekanje in draženje stene malih dihalnih poti (vnetje), kar vodi v simptome kot so kašljanje, piskanje, stiskanje v prsnem košu ali težko dihanje.
Vomiting Gastro-esophageal reflux disease Dyspepsia
Bolezni prebavil driska navzea bolečine v trebuhu gastritis bruhanje gastroezofagealna refluksna bolezen dispepsija hematohezija zaprtost
The risks and benefits of starting or continuing treatment with roflumilast should be carefully assessed if patients report previous or existing psychiatric symptoms or if concomitant treatment with other medicinal products likely to cause psychiatric events is intended.
Če bolniki navajajo psihiatrične simptome v preteklosti ali sedanjosti ali če se predvideva zdravljenje z drugimi zdravili, ki lahko povzročijo psihiatrične dogodke, je treba skrbno pretehtati tveganja in koristi glede začetka ali nadaljevanja zdravljenja z roflumilastom.
daxas 500 mcg
Daxas 500 mikrogramov
Rate Ratio
Razmerje deležev
Roflumilast did not significantly reduce the rate of exacerbations compared with placebo in the subgroup of patients with moderate COPD.
V podskupini bolnikov z zmerno obliko KOPB roflumilast ni statistično pomembno zmanjšal pogostnosti poslabšanj v primerjavi s placebom.
Endocrine disorders
Bolezni endokrinega sistema ginekomastija
You may experience diarrhoea, nausea, stomach ache or headache during the first weeks of treatment with Daxas.
V prvih tednih zdravljenja z zdravilom Daxas boste morda imeli drisko, slabost, bolečine v trebuhu ali glavobol.
Each tablet contains 500 micrograms roflumilast.
Ena tableta vsebuje 500 mikrogramov roflumilasta.
Daxas 250 micrograms tablets
Daxas 250 mikrogramov tablete
Daxas 500 micrograms film-coated tablets
Daxas 500 mikrogramov filmsko obložene tablete
Each tablet contains 250 micrograms roflumilast.
Ena tableta vsebuje 250 mikrogramov roflumilasta.
Roflumilast has been demonstrated to cross the placenta in pregnant rats.
Pri brejih podganah so ugotovili, da roflumilast prehaja skozi placento.
Daxas 500 micrograms film-coated tablets Roflumilast
Daxas 500 mikrogramov filmsko obložene tablete roflumilast
OUTER CARTON FOR BLISTER
ŠKATLA ZA PRETISNE OMOTE
Daxas 500 micrograms tablets roflumilast
Daxas 500 mikrogramov tablete roflumilast
You should talk to your doctor, if you are diagnosed with any of these diseases.
Če imate diagnosticirano katero od teh bolezni, se morate posvetovati z zdravnikom.
Daxas 250 micrograms tablets roflumilast
Daxas 250 mikrogramov tablete roflumilast
• For the first 28 days - the recommended starting dose is one 250 micrograms tablet once daily.
• Prvih 28 dni - Priporočeni začetni odmerek je ena tableta 250 mikrogramov enkrat na dan. - Začetni odmerek je majhen odmerek, ki se uporablja, da se telo navadi na zdravilo, preden začnete jemati polni odmerek.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially the following: - a medicine containing theophylline (a medicine to treat respiratory diseases), or - a medicine used for treatment of immunological diseases, such as methotrexate, azathioprine, infliximab, etanercept, or oral corticosteroids to be taken long-term.
Še posebej pozorni bodite na naslednja: - zdravilo, ki vsebuje teofilin (zdravilo za zdravljenje bolezni dihal), - zdravila, ki se uporabljajo za zdravljenje bolezni imunskega sistema, kot so metotreksat,
Gastrointestinal disorders Diarrhoea Nausea
Bolezni imunskega sistema preobčutljivost angioedem
Final study report by 31/03/2021.
Končno poročilo o študiji do
Please talk to your doctor if you have one of these diseases.
Če imate katero od teh bolezni, se posvetujte z zdravnikom.
Severe
Hudo
*A single case with a fatal outcome
*En sam primer s smrtnim izidom
Approximately 30% of patients experienced at least one adverse reaction.
Približno 30 % bolnikov je doživelo vsaj en neželeni učinek.
Interaction studies have been conducted in healthy volunteers.
Študije interakcije so izvedli pri zdravih prostovoljcih.
Constipation may be a preceding symptom.
Zaprtje je lahko predhodni simptom.
Just carry on with the next dose at the normal time.
Nadaljujte z naslednjim odmerkom ob običajnem času.
Long-term studies:
Dolgoročne študije:
These measures will help to protect the environment and to prevent accidental access by children.
Taki ukrepi pomagajo varovati okolje in preprečijo neželeni dostop otrokom.
If you do not regularly eat three meals per day then please tell your doctor.
Če ne uživate redno treh obrokov na dan, to povejte svojemu zdravniku.
Experience from clinical studies in patients above the age of 75 years is very limited.
Izkušnje iz kliničnih študij pri bolnikih, starih več kot 75 let, so zelo omejene.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 21 January 2013
Datum prve odobritve: 21. januar 2013
Your doctor may decide to increase this up to a total dose of 15 g per day depending on the level of phosphorus in your blood.
Vaš zdravnik se lahko odloči, da bo odmerek povečal do skupnega odmerka 15 g na dan, odvisno od ravni fosforja v vaši krvi.
Do not take a double dose to make up for forgotten doses.
Ne vzemite dvojnega odmerka, če ste pozabili vzeti odmerek.
After one year of treatment, a reduction of 1.12% in HbA1c was observed.
Po enem letu zdravljenja so opazili znižanje HbA1c za 1,12 %.
The potential risk of overdosing could include adverse reactions or a worsening of adverse reactions mentioned in section 4.8.
Možno tveganje za preveliko odmerjanje lahko vključuje neželene reakcije ali poslabšanje neželenih učinkov, omenjenih v poglavju 4.8.
Systemic ion balance
Sistemsko ionsko ravnovesje
In patients who develop severe constipation or other severe gastrointestinal symptoms, alternative treatment may need to be considered.
Pri bolnikih, pri katerih se razvije hudo zaprtje ali drugi resni gastrointestinalni simptomi, je treba morda razmisliti o alternativnem zdravljenju.
Pharmacotherapeutic group: not yet assigned.
Farmakoterapevtska skupina: še ni bila dodeljena.
Interactions have not been studied at doses >9 g daily, and greater interaction effects at higher doses of BindRen cannot be excluded.
Interakcij niso preučili pri odmerkih >9 g na dan, zato večjega učinka interakcij pri višjih odmerkih zdravila BindRen ni mogoče izključiti.
- you have abnormally low levels of calcium in your blood.
- imate nenormalno nizke ravni kalcija v krvi.
• Severe hepatic impairment (see also section 4.2)
• hudo okvaro jeter (glejte tudi poglavje 4.2),
The frequency of adverse reactions increased with dose.
Pogostnost neželenih učinkov je naraščala z odmerkom.
• Serum albumin <30 g/L
• z albuminom v serumu <30 g/l.
BindRen lowered the bioavailability of digoxin by 16% and Cmax by 17%, and the Cmax of enalapril by 27%.
Zdravilo BindRen je zmanjšalo biološko razpoložljivost digoksina za 16 % in Cmax za 17 %, Cmax enalaprila pa za 27 %.
However, other effects of BindRen may affect pregnant and breast-feeding women or influence fertility, see sections 4.4 and 4.5.
Vendar pa lahko drugi učinki zdravila BindRen vplivajo na noseče ali doječe ženske ali na plodnost, glejte poglavji 4.4 in 4.5.
45 film-coated tablets 99 film-coated tablets 198 film-coated tablets 270 film-coated tablets 297 film-coated tablets
45 filmsko obloženih tablet 99 filmsko obloženih tablet 198 filmsko obloženih tablet 270 filmsko obloženih tablet 297 filmsko obloženih tablet
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO
Your doctor may consider measuring blood levels of the other medicines you are taking.
Vaš zdravnik vam bo morda izmeril ravni drugih zdravil, ki jih jemljete, v krvi.
Allergic dermatitis, guttae psoriasis
alergijski dermatitis, gutatna psoriaza
Hypocalcaemia, decreased appetite
hipokalciemija, zmanjšanje apetita
You have also been advised to follow a special diet to reduce the amount of phosphorus that your body takes from food.
Svetovali so vam tudi, da se držite posebne diete, s katero znižate količino fosforja, ki ga vnesete v telo s hrano.
BindRen is not absorbed and is not systemically available.
Zdravilo BindRen se ne absorbira in ni sistemsko razpoložljivo.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obvestite svojega zdravnika ali farmacevta, če uporabljate, ste pred kratkim uporabljali ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
It is important that you continue taking BindRen for as long as your doctor prescribes the medicine and to keep to your diet.
Pomembno je, da nadaljujete z jemanjem zdravila BindRen, dokler vam je zdravnik zdravilo predpisal, in da se držite svoje diete.
A majority of patients received 12 or 15 g/day of colestilan in the long-term studies.
Večina bolnikov je v dolgoročnih študijah prejemala 12 ali 15 g kolestilana na dan.
Three Phase III studies and two long term follow-up studies have been performed in patients with CKD Stage 5 on dialysis, in order to investigate efficacy and safety in this population.
Izvedli so tri študije III faze in dve dolgoročni spremljevalni študiji z bolniki s KBL 5. faze na dializi, da bi raziskali učinkovitost in varnost v tej populaciji.
However, reproductive toxicity studies were not conducted at doses higher than 2.5 times the human clinical dose, and the possible reproductive effects related to coagulation and bleeding have not been assessed.
Vendar pa študij toksičnosti niso izvedli pri odmerkih, višjih kot 2,5-krat od kliničnega odmerka za človeka, možnih učinkov na sposobnost razmnoževanja, povezanih s koagulacijo in krvavitvijo, pa niso ocenili.
Sometimes, the dialysis and diet are not enough to stop the phosphorus in your blood rising to high levels, a condition referred to by your doctor as hyperphosphataemia.
Včasih dializa in dieta ne zadoščata za ustavitev naraščanja fosforja v krvi do visokih ravni, kar je stanje, ki ga zdravnik imenuje hiperfosfatemija.
- you have been told that you have a disorder that decreases the intestines ability to absorb nutrients (malabsorption syndrome) or if you are treated with so called coumarin anticoagulants (e.g. warfarin), since your doctor may want to monitor your blood and possibly ask you to start taking vitamin supplements.
- povedali so vam, da imate bolezen, ki zmanjša sposobnost absorpcije hranil v črevesje (malabsorpcijski sindrom) ali če so vas zdravili s t.i. kumarin anticoagulanti (npr. warfarin), ker želi vaš zdravnik spremljati kri in vas bo morda prosil, da začnete jemati vitaminske dodatke.
The results of in vitro testing suggest that medicinal products with anionic and/or lipophilic characteristics have a higher potential to bind to BindRen.
Rezultati testiranja in vitro kažejo, da imajo zdravila z anionskimi in/ali lipofilnimi značilnostmi višji potencial za vezavo na zdravilo BindRen.
Keeping the phosphorus level in your blood low is important to maintain healthy bones and blood vessels and to prevent itchy skin, red eyes, bone pain or bone fractures.
Ohranjanje nizkih ravni fosforja v krvi je pomembno za ohranjanje zdravih kosti in krvnih žil ter za preprečevanje srbeče kože, rdečih oči, bolečini v kosteh ali zlomov kosti.
The division of the daily dose may be adjusted on a physician's advice taking into account the dietary intake of phosphate.
Razdelitev dnevnega odmerka se lahko prilagodi po nasvetu zdravnika ob upoštevanju vnosa fosfata s hrano.
Other medicines and BindRen
Druga zdravila in zdravilo BindRen
Therefore, the use of BindRen is not recommended in patients with these disorders.
Zato se uporaba zdravila BindRen pri bolnikih s temi boleznimi ne priporoča.